Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%

MT Newswires Live

Yesterday

China's National Medical Products Administration accepted Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.

The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.

Fosun's subsidiary, Shanghai Henlius Biotech, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.K. and Canada.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.etasphere.com/news/2667637538"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667637538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667637538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 12:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667637538","market":"fut","top_or_hot":-1,"title":"Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration accepted <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical's (HKG:2196, SHA:600196) application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.</p><p>The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.</p><p>Fosun's subsidiary, <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a>, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. and Canada.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Drug Regulator Accepts Fosun Pharma's Application for HLX14; Shares Up 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-14 12:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration accepted <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical's (HKG:2196, SHA:600196) application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.</p><p>The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.</p><p>Fosun's subsidiary, <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a>, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. and Canada.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667637538","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667637538","pubTimestamp":1789361006,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration accepted Shanghai Fosun Pharmaceutical's  application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.Fosun's subsidiary, Shanghai Henlius Biotech, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.K. and Canada.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0187":"一线龙头","BK1191":"制药","BK0096":"民营医院","BK1515":"抗疫概念","BK0188":"融资融券","BK1593":"医美概念股","BK0175":"白马股","02196":"复星医药","BK0196":"行业龙头","BK0060":"抗癌","BK0012":"证金概念"},"translate_title":"中国药品监管机构受理复星医药HLX14的申请；股价上涨 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9},"content_text":"China's National Medical Products Administration accepted Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) application for the 120 milligram per vial of HLX14, or recombinant anti-RANKL fully human monoclonal antibody injection, according to a Shanghai bourse filing on the weekend.The pharmaceutical company's Hong Kong shares jumped 5%, while Shanghai shares rose 2% during Monday's midday trade.Fosun's subsidiary, Shanghai Henlius Biotech, developed the drug, which has been approved for marketing in the U.S., the European Union, the U.K. and Canada.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}